AbCellera Biologics (ABCL) Accumulated Depreciation (2020 - 2022)

Historic Accumulated Depreciation for AbCellera Biologics (ABCL) over the last 3 years, with Q4 2022 value amounting to $18.5 million.

  • AbCellera Biologics' Accumulated Depreciation rose 8802.16% to $18.5 million in Q4 2022 from the same period last year, while for Dec 2022 it was $18.5 million, marking a year-over-year increase of 8802.16%. This contributed to the annual value of $18.5 million for FY2022, which is 8802.16% up from last year.
  • According to the latest figures from Q4 2022, AbCellera Biologics' Accumulated Depreciation is $18.5 million, which was up 8802.16% from $15.7 million recorded in Q3 2022.
  • In the past 5 years, AbCellera Biologics' Accumulated Depreciation registered a high of $18.5 million during Q4 2022, and its lowest value of $5.6 million during Q4 2020.
  • Over the past 3 years, AbCellera Biologics' median Accumulated Depreciation value was $9.8 million (recorded in 2021), while the average stood at $10.7 million.
  • Per our database at Business Quant, AbCellera Biologics' Accumulated Depreciation skyrocketed by 7590.4% in 2021 and then soared by 8802.16% in 2022.
  • AbCellera Biologics' Accumulated Depreciation (Quarter) stood at $5.6 million in 2020, then skyrocketed by 75.9% to $9.8 million in 2021, then soared by 88.02% to $18.5 million in 2022.
  • Its Accumulated Depreciation was $18.5 million in Q4 2022, compared to $15.7 million in Q3 2022 and $13.2 million in Q2 2022.